The bioinformatics data also revealed that the mutation in APCMin/+ accounted for 20.4% of CRC patients with CRC (Figure S5A) and that TP53 mutation accounted for 44.4% (Figure 5B). Here, TP53 is linked to colorectal carcinoma.